Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial
Paracetamol poisoning is common worldwide. It is treated with intravenous acetylcysteine, but the standard regimen is complex and associated with frequent adverse effects related to concentration, which can cause treatment interruption. We aimed to ascertain whether adverse effects could be reduced...
Saved in:
| Published in: | The Lancet (British edition) Vol. 383; no. 9918; pp. 697 - 704 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Kidlington
Elsevier Ltd
22.02.2014
Elsevier Elsevier Limited |
| Subjects: | |
| ISSN: | 0140-6736, 1474-547X, 1474-547X |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Paracetamol poisoning is common worldwide. It is treated with intravenous acetylcysteine, but the standard regimen is complex and associated with frequent adverse effects related to concentration, which can cause treatment interruption. We aimed to ascertain whether adverse effects could be reduced with either a shorter modified acetylcysteine schedule, antiemetic pretreatment, or both.
We undertook a double-blind, randomised factorial study at three UK hospitals, between Sept 6, 2010, and Dec 31, 2012. We randomly allocated patients with acute paracetamol overdose to either the standard intravenous acetylcysteine regimen (duration 20·25 h) or a shorter (12 h) modified protocol, with or without intravenous ondansetron pretreatment (4 mg). Masking was achieved by infusion of 5% dextrose (during acetylcysteine delivery) or saline (for antiemetic pretreatment). Randomisation was done via the internet and included a minimisation procedure by prognostic factors. The primary outcome was absence of vomiting, retching, or need for rescue antiemetic treatment at 2 h. Prespecified secondary outcomes included a greater than 50% increase in alanine aminotransferase activity over the admission value. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov (identifier NCT01050270).
Of 222 patients who underwent randomisation, 217 were assessable 2 h after the start of acetylcysteine treatment. Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13–0·52; p<0·0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20–0·80; p=0·003). Severe anaphylactoid reactions were recorded in five patients assigned to the shorter modified acetylcysteine regimen versus 31 who were allocated to the standard protocol (adjusted common odds ratio 0·23, 97·5% CI 0·12–0·43; p<0·0001). The proportion of patients with a 50% increase in alanine aminotransferase activity did not differ between the standard (13/101) and shorter modified (9/100) regimens (adjusted odds ratio 0·60, 97·5% CI 0·20–1·83); however, the proportion was higher with ondansetron (16/100) than with placebo (6/101; 3·30, 1·01–10·72; p=0·024).
In patients with paracetamol poisoning, a 12 h modified acetylcysteine regimen resulted in less vomiting, fewer anaphylactoid reactions, and reduced need for treatment interruption. This study was not powered to detect non-inferiority of the shorter protocol versus the standard approach; therefore, further research is needed to confirm the efficacy of the 12 h modified acetylcysteine regimen.
Chief Scientist Office of the Scottish Government. |
|---|---|
| AbstractList | Paracetamol poisoning is common worldwide. It is treated with intravenous acetylcysteine, but the standard regimen is complex and associated with frequent adverse effects related to concentration, which can cause treatment interruption. We aimed to ascertain whether adverse effects could be reduced with either a shorter modified acetylcysteine schedule, antiemetic pretreatment, or both.
We undertook a double-blind, randomised factorial study at three UK hospitals, between Sept 6, 2010, and Dec 31, 2012. We randomly allocated patients with acute paracetamol overdose to either the standard intravenous acetylcysteine regimen (duration 20·25 h) or a shorter (12 h) modified protocol, with or without intravenous ondansetron pretreatment (4 mg). Masking was achieved by infusion of 5% dextrose (during acetylcysteine delivery) or saline (for antiemetic pretreatment). Randomisation was done via the internet and included a minimisation procedure by prognostic factors. The primary outcome was absence of vomiting, retching, or need for rescue antiemetic treatment at 2 h. Prespecified secondary outcomes included a greater than 50% increase in alanine aminotransferase activity over the admission value. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov (identifier NCT01050270).
Of 222 patients who underwent randomisation, 217 were assessable 2 h after the start of acetylcysteine treatment. Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13–0·52; p<0·0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20–0·80; p=0·003). Severe anaphylactoid reactions were recorded in five patients assigned to the shorter modified acetylcysteine regimen versus 31 who were allocated to the standard protocol (adjusted common odds ratio 0·23, 97·5% CI 0·12–0·43; p<0·0001). The proportion of patients with a 50% increase in alanine aminotransferase activity did not differ between the standard (13/101) and shorter modified (9/100) regimens (adjusted odds ratio 0·60, 97·5% CI 0·20–1·83); however, the proportion was higher with ondansetron (16/100) than with placebo (6/101; 3·30, 1·01–10·72; p=0·024).
In patients with paracetamol poisoning, a 12 h modified acetylcysteine regimen resulted in less vomiting, fewer anaphylactoid reactions, and reduced need for treatment interruption. This study was not powered to detect non-inferiority of the shorter protocol versus the standard approach; therefore, further research is needed to confirm the efficacy of the 12 h modified acetylcysteine regimen.
Chief Scientist Office of the Scottish Government. Paracetamol poisoning is common worldwide. It is treated with intravenous acetylcysteine, but the standard regimen is complex and associated with frequent adverse effects related to concentration, which can cause treatment interruption. We aimed to ascertain whether adverse effects could be reduced with either a shorter modified acetylcysteine schedule, antiemetic pretreatment, or both.BACKGROUNDParacetamol poisoning is common worldwide. It is treated with intravenous acetylcysteine, but the standard regimen is complex and associated with frequent adverse effects related to concentration, which can cause treatment interruption. We aimed to ascertain whether adverse effects could be reduced with either a shorter modified acetylcysteine schedule, antiemetic pretreatment, or both.We undertook a double-blind, randomised factorial study at three UK hospitals, between Sept 6, 2010, and Dec 31, 2012. We randomly allocated patients with acute paracetamol overdose to either the standard intravenous acetylcysteine regimen (duration 20·25 h) or a shorter (12 h) modified protocol, with or without intravenous ondansetron pretreatment (4 mg). Masking was achieved by infusion of 5% dextrose (during acetylcysteine delivery) or saline (for antiemetic pretreatment). Randomisation was done via the internet and included a minimisation procedure by prognostic factors. The primary outcome was absence of vomiting, retching, or need for rescue antiemetic treatment at 2 h. Prespecified secondary outcomes included a greater than 50% increase in alanine aminotransferase activity over the admission value. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov (identifier NCT01050270).METHODSWe undertook a double-blind, randomised factorial study at three UK hospitals, between Sept 6, 2010, and Dec 31, 2012. We randomly allocated patients with acute paracetamol overdose to either the standard intravenous acetylcysteine regimen (duration 20·25 h) or a shorter (12 h) modified protocol, with or without intravenous ondansetron pretreatment (4 mg). Masking was achieved by infusion of 5% dextrose (during acetylcysteine delivery) or saline (for antiemetic pretreatment). Randomisation was done via the internet and included a minimisation procedure by prognostic factors. The primary outcome was absence of vomiting, retching, or need for rescue antiemetic treatment at 2 h. Prespecified secondary outcomes included a greater than 50% increase in alanine aminotransferase activity over the admission value. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov (identifier NCT01050270).Of 222 patients who underwent randomisation, 217 were assessable 2 h after the start of acetylcysteine treatment. Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13-0·52; p<0·0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20-0·80; p=0·003). Severe anaphylactoid reactions were recorded in five patients assigned to the shorter modified acetylcysteine regimen versus 31 who were allocated to the standard protocol (adjusted common odds ratio 0·23, 97·5% CI 0·12-0·43; p<0·0001). The proportion of patients with a 50% increase in alanine aminotransferase activity did not differ between the standard (9/110) and shorter modified (13/112) regimens (adjusted odds ratio 0·60, 97·5% CI 0·20-1·83); however, the proportion was higher with ondansetron (16/111) than with placebo (6/111; 3·30, 1·01-10·72; p=0·024).FINDINGSOf 222 patients who underwent randomisation, 217 were assessable 2 h after the start of acetylcysteine treatment. Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13-0·52; p<0·0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20-0·80; p=0·003). Severe anaphylactoid reactions were recorded in five patients assigned to the shorter modified acetylcysteine regimen versus 31 who were allocated to the standard protocol (adjusted common odds ratio 0·23, 97·5% CI 0·12-0·43; p<0·0001). The proportion of patients with a 50% increase in alanine aminotransferase activity did not differ between the standard (9/110) and shorter modified (13/112) regimens (adjusted odds ratio 0·60, 97·5% CI 0·20-1·83); however, the proportion was higher with ondansetron (16/111) than with placebo (6/111; 3·30, 1·01-10·72; p=0·024).In patients with paracetamol poisoning, a 12 h modified acetylcysteine regimen resulted in less vomiting, fewer anaphylactoid reactions, and reduced need for treatment interruption. This study was not powered to detect non-inferiority of the shorter protocol versus the standard approach; therefore, further research is needed to confirm the efficacy of the 12 h modified acetylcysteine regimen.INTERPRETATIONIn patients with paracetamol poisoning, a 12 h modified acetylcysteine regimen resulted in less vomiting, fewer anaphylactoid reactions, and reduced need for treatment interruption. This study was not powered to detect non-inferiority of the shorter protocol versus the standard approach; therefore, further research is needed to confirm the efficacy of the 12 h modified acetylcysteine regimen.Chief Scientist Office of the Scottish Government.FUNDINGChief Scientist Office of the Scottish Government. Summary Background Paracetamol poisoning is common worldwide. It is treated with intravenous acetylcysteine, but the standard regimen is complex and associated with frequent adverse effects related to concentration, which can cause treatment interruption. We aimed to ascertain whether adverse effects could be reduced with either a shorter modified acetylcysteine schedule, antiemetic pretreatment, or both. Methods We undertook a double-blind, randomised factorial study at three UK hospitals, between Sept 6, 2010, and Dec 31, 2012. We randomly allocated patients with acute paracetamol overdose to either the standard intravenous acetylcysteine regimen (duration 20·25 h) or a shorter (12 h) modified protocol, with or without intravenous ondansetron pretreatment (4 mg). Masking was achieved by infusion of 5% dextrose (during acetylcysteine delivery) or saline (for antiemetic pretreatment). Randomisation was done via the internet and included a minimisation procedure by prognostic factors. The primary outcome was absence of vomiting, retching, or need for rescue antiemetic treatment at 2 h. Prespecified secondary outcomes included a greater than 50% increase in alanine aminotransferase activity over the admission value. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov (identifier NCT01050270). Findings Of 222 patients who underwent randomisation, 217 were assessable 2 h after the start of acetylcysteine treatment. Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13–0·52; p<0·0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20–0·80; p=0·003). Severe anaphylactoid reactions were recorded in five patients assigned to the shorter modified acetylcysteine regimen versus 31 who were allocated to the standard protocol (adjusted common odds ratio 0·23, 97·5% CI 0·12–0·43; p<0·0001). The proportion of patients with a 50% increase in alanine aminotransferase activity did not differ between the standard (13/101) and shorter modified (9/100) regimens (adjusted odds ratio 0·60, 97·5% CI 0·20–1·83); however, the proportion was higher with ondansetron (16/100) than with placebo (6/101; 3·30, 1·01–10·72; p=0·024). Interpretation In patients with paracetamol poisoning, a 12 h modified acetylcysteine regimen resulted in less vomiting, fewer anaphylactoid reactions, and reduced need for treatment interruption. This study was not powered to detect non-inferiority of the shorter protocol versus the standard approach; therefore, further research is needed to confirm the efficacy of the 12 h modified acetylcysteine regimen. Funding Chief Scientist Office of the Scottish Government. Paracetamol poisoning is common worldwide. It is treated with intravenous acetylcysteine, but the standard regimen is complex and associated with frequent adverse effects related to concentration, which can cause treatment interruption. We aimed to ascertain whether adverse effects could be reduced with either a shorter modified acetylcysteine schedule, antiemetic pretreatment, or both. We undertook a double-blind, randomised factorial study at three UK hospitals, between Sept 6, 2010, and Dec 31, 2012. We randomly allocated patients with acute paracetamol overdose to either the standard intravenous acetylcysteine regimen (duration 20·25 h) or a shorter (12 h) modified protocol, with or without intravenous ondansetron pretreatment (4 mg). Masking was achieved by infusion of 5% dextrose (during acetylcysteine delivery) or saline (for antiemetic pretreatment). Randomisation was done via the internet and included a minimisation procedure by prognostic factors. The primary outcome was absence of vomiting, retching, or need for rescue antiemetic treatment at 2 h. Prespecified secondary outcomes included a greater than 50% increase in alanine aminotransferase activity over the admission value. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov (identifier NCT01050270). Of 222 patients who underwent randomisation, 217 were assessable 2 h after the start of acetylcysteine treatment. Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13-0·52; p<0·0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20-0·80; p=0·003). Severe anaphylactoid reactions were recorded in five patients assigned to the shorter modified acetylcysteine regimen versus 31 who were allocated to the standard protocol (adjusted common odds ratio 0·23, 97·5% CI 0·12-0·43; p<0·0001). The proportion of patients with a 50% increase in alanine aminotransferase activity did not differ between the standard (9/110) and shorter modified (13/112) regimens (adjusted odds ratio 0·60, 97·5% CI 0·20-1·83); however, the proportion was higher with ondansetron (16/111) than with placebo (6/111; 3·30, 1·01-10·72; p=0·024). In patients with paracetamol poisoning, a 12 h modified acetylcysteine regimen resulted in less vomiting, fewer anaphylactoid reactions, and reduced need for treatment interruption. This study was not powered to detect non-inferiority of the shorter protocol versus the standard approach; therefore, further research is needed to confirm the efficacy of the 12 h modified acetylcysteine regimen. Chief Scientist Office of the Scottish Government. Paracetamol poisoning is common worldwide. It is treated with intravenous acetylcysteine, but the standard regimen is complex and associated with frequent adverse effects related to concentration, which can cause treatment interruption. We aimed to ascertain whether adverse effects could be reduced with either a shorter modified acetylcysteine schedule, antiemetic pretreatment, or both. Methods We undertook a double-blind, randomised factorial study at three UK hospitals, between Sept 6, 2010, and Dec 31, 2012. We randomly allocated patients with acute paracetamol overdose to either the standard intravenous acetylcysteine regimen (duration 20·25 h) or a shorter (12 h) modified protocol, with or without intravenous ondansetron pretreatment (4 mg). Masking was achieved by infusion of 5% dextrose (during acetylcysteine delivery) or saline (for antiemetic pretreatment). Randomisation was done via the internet and included a minimisation procedure by prognostic factors. The primary outcome was absence of vomiting, retching, or need for rescue antiemetic treatment at 2 h. Prespecified secondary outcomes included a greater than 50% increase in alanine aminotransferase activity over the admission value. Analysis was by intention to treat. This trial is registered withClinicalTrials.gov(identifierNCT01050270). Findings Of 222 patients who underwent randomisation, 217 were assessable 2 h after the start of acetylcysteine treatment. Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13-0·52; p<0·0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20-0·80; p=0·003). Severe anaphylactoid reactions were recorded in five patients assigned to the shorter modified acetylcysteine regimen versus 31 who were allocated to the standard protocol (adjusted common odds ratio 0·23, 97·5% CI 0·12-0·43; p<0·0001). The proportion of patients with a 50% increase in alanine aminotransferase activity did not differ between the standard (9/110) and shorter modified (13/112) regimens (adjusted odds ratio 0·60, 97·5% CI 0·20-1·83); however, the proportion was higher with ondansetron (16/111) than with placebo (6/111; 3·30, 1·01-10·72; p=0·024). Interpretation In patients with paracetamol poisoning, a 12 h modified acetylcysteine regimen resulted in less vomiting, fewer anaphylactoid reactions, and reduced need for treatment interruption. This study was not powered to detect non-inferiority of the shorter protocol versus the standard approach; therefore, further research is needed to confirm the efficacy of the 12 h modified acetylcysteine regimen. Funding Chief Scientist Office of the Scottish Government. Paracetamol poisoning is common worldwide. It is treated with intravenous acetylcysteine, but the standard regimen is complex and associated with frequent adverse effects related to concentration, which can cause treatment interruption. We aimed to ascertain whether adverse effects could be reduced with either a shorter modified acetylcysteine schedule, antiemetic pretreatment, or both. Methods: We undertook a double-blind, randomised factorial study at three UK hospitals, between Sept 6, 2010, and Dec 31, 2012. We randomly allocated patients with acute paracetamol overdose to either the standard intravenous acetylcysteine regimen (duration 20·25 h) or a shorter (12 h) modified protocol, with or without intravenous ondansetron pretreatment (4 mg). Masking was achieved by infusion of 5% dextrose (during acetylcysteine delivery) or saline (for antiemetic pretreatment). Randomisation was done via the internet and included a minimisation procedure by prognostic factors. The primary outcome was absence of vomiting, retching, or need for rescue antiemetic treatment at 2 h. Prespecified secondary outcomes included a greater than 50% increase in alanine aminotransferase activity over the admission value. Analysis was by intention to treat. This trial is registered withClinicalTrials.gov(identifierNCT01050270). Findings: Of 222 patients who underwent randomisation, 217 were assessable 2 h after the start of acetylcysteine treatment. Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13-0·52; p<0· ;0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20-0·80; p=0·003). Severe anaphylactoid reactions were recorded in five patients assigned to the shorter modified acetylcysteine regimen versus 31 who were allocated to the standard protocol (adjusted common odds ratio 0·23, 97·5% CI 0·12-0·43; p<0·0001). The proportion of patients with a 50% increase in alanine aminotransferase activity did not differ between the standard (9/110) and shorter modified (13/112) regimens (adjusted odds ratio 0·60, 97·5% CI 0·20-1·83); however, the proportion was higher with ondansetron (16/111) than with placebo (6/111; 3·30, 1·01-10·72; p=0·024). Interpretation: In patients with paracetamol poisoning, a 12 h modified acetylcysteine regimen resulted in less vomiting, fewer anaphylactoid reactions, and reduced need for treatment interruption. This study was not powered to detect non-inferiority of the shorter protocol versus the standard approach; therefore, further research is needed to confirm the efficacy of the 12 h modified acetylcysteine regimen. 30 references |
| Author | Coyle, Judy Veiraiah, Aravindan Thomas, Simon H L Lewis, Steff C Rodriguez, Aryelly Sandilands, Euan A Cooper, Jamie G Eddleston, Michael Webb, David J Gray, Alasdair Butcher, Isabella Bateman, D Nicholas Dear, James W Thanacoody, H K Ruben Vliegenthart, A D Bastiaan |
| Author_xml | – sequence: 1 givenname: D Nicholas surname: Bateman fullname: Bateman, D Nicholas email: spib@luht.scot.nhs.uk organization: National Poisons Information Service, Royal Infirmary of Edinburgh, Edinburgh, UK – sequence: 2 givenname: James W surname: Dear fullname: Dear, James W organization: National Poisons Information Service, Royal Infirmary of Edinburgh, Edinburgh, UK – sequence: 3 givenname: H K Ruben surname: Thanacoody fullname: Thanacoody, H K Ruben organization: Institute of Cellular Medicine, Newcastle University, and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK – sequence: 4 givenname: Simon H L surname: Thomas fullname: Thomas, Simon H L organization: Institute of Cellular Medicine, Newcastle University, and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK – sequence: 5 givenname: Michael surname: Eddleston fullname: Eddleston, Michael organization: National Poisons Information Service, Royal Infirmary of Edinburgh, Edinburgh, UK – sequence: 6 givenname: Euan A surname: Sandilands fullname: Sandilands, Euan A organization: National Poisons Information Service, Royal Infirmary of Edinburgh, Edinburgh, UK – sequence: 7 givenname: Judy surname: Coyle fullname: Coyle, Judy organization: Emergency Medicine Research Group, Department of Emergency Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK – sequence: 8 givenname: Jamie G surname: Cooper fullname: Cooper, Jamie G organization: Emergency Department, Aberdeen Royal Infirmary, Aberdeen, UK – sequence: 9 givenname: Aryelly surname: Rodriguez fullname: Rodriguez, Aryelly organization: Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK – sequence: 10 givenname: Isabella surname: Butcher fullname: Butcher, Isabella organization: Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK – sequence: 11 givenname: Steff C surname: Lewis fullname: Lewis, Steff C organization: Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK – sequence: 12 givenname: A D Bastiaan surname: Vliegenthart fullname: Vliegenthart, A D Bastiaan organization: British Heart Foundation Centre for Cardiovascular Science, Edinburgh University, Edinburgh, UK – sequence: 13 givenname: Aravindan surname: Veiraiah fullname: Veiraiah, Aravindan organization: National Poisons Information Service, Royal Infirmary of Edinburgh, Edinburgh, UK – sequence: 14 givenname: David J surname: Webb fullname: Webb, David J organization: British Heart Foundation Centre for Cardiovascular Science, Edinburgh University, Edinburgh, UK – sequence: 15 givenname: Alasdair surname: Gray fullname: Gray, Alasdair organization: Emergency Medicine Research Group, Department of Emergency Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28175154$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24290406$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl1rFDEUhgep2G31JygBEerFaM5MMrNTUZHiFxQEP8C7kE1OJDWTrEl2Ya_862Z2txYK2l5NYJ7zJOec96g68MFjVT0E-gwodM-_UGC07vq2O4H2adfQrqnpnWoGrGc1Z_33g2r2FzmsjlK6oJSyjvJ71WHDmoEy2s2q359Rr1S2wZNgiNRrjAkJGoMqJ2JiGIn1Oco1-rBKRCrMG6c2KaP1SHJEmUf0mZgQyVLG6b8cgyPLYFPw1v84JZJE6XUYbUJNVCi24Fw55milu1_dNdIlfLD_Hlff3r39evahPv_0_uPZm_NadYzmmi9gMFwb2jNpGEqlF9BLM_QDgOTAqTJKS4SFaebA0AAYyXRpk88Z17Boj6uTnXcZw68VpizKexQ6Jz2WxgTwpmVlPrS5BUph3vactwV9fA29CKvoSyOiBQ5FN6fD_6jiKkjPBl6oR3tqtRhRi2W0o4wbcbmrAjzZAzIp6UyZqrLpiptDXybBCvdix6kYUopohLJZTisue7ROABVTgsQ2QWKKh4BWbBMkaKnm16ovL7ip7vWuDssW1xajSMqiV6htLFkSOtgbDa-uGZSz3pZWf-IG09XMRCr4TjI5oN0aJsHLfwtu8YA_KFMFoA |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1002_cld_373 crossref_primary_10_1080_15563650_2025_2456116 crossref_primary_10_1007_s11244_023_01887_4 crossref_primary_10_1111_bcp_13099 crossref_primary_10_1089_neu_2014_3855 crossref_primary_10_1016_j_jchromb_2015_04_031 crossref_primary_10_1002_cpt_541 crossref_primary_10_1080_15563650_2017_1408812 crossref_primary_10_1007_s00228_017_2277_4 crossref_primary_10_1111_cbdd_14369 crossref_primary_10_1186_s13063_018_3134_1 crossref_primary_10_1039_C9TX00002J crossref_primary_10_1002_psp4_12298 crossref_primary_10_1016_j_clinthera_2015_07_012 crossref_primary_10_1177_15353702221147563 crossref_primary_10_1007_s00204_014_1432_2 crossref_primary_10_1016_j_resconrec_2020_104862 crossref_primary_10_1016_j_intimp_2025_115070 crossref_primary_10_3389_fphar_2022_828565 crossref_primary_10_3390_livers5020020 crossref_primary_10_1016_j_cbi_2015_11_002 crossref_primary_10_1016_j_toxlet_2016_06_1232 crossref_primary_10_1586_17474124_2016_1127756 crossref_primary_10_1080_17425255_2022_2151893 crossref_primary_10_1007_s13181_018_0653_9 crossref_primary_10_1039_c9tx00216b crossref_primary_10_12968_hmed_2022_0313 crossref_primary_10_1016_j_ajem_2020_04_061 crossref_primary_10_1016_j_mehy_2020_109862 crossref_primary_10_1016_j_plabm_2015_12_003 crossref_primary_10_1016_j_ebiom_2019_07_013 crossref_primary_10_3390_pediatric16010020 crossref_primary_10_1053_j_gastro_2016_12_027 crossref_primary_10_1155_2021_3320325 crossref_primary_10_1002_hep_30224 crossref_primary_10_1097_FAD_0000000000000054 crossref_primary_10_1080_15563650_2018_1475672 crossref_primary_10_1080_15563650_2023_2259085 crossref_primary_10_1136_bmjopen_2024_097432 crossref_primary_10_1080_15563650_2019_1594873 crossref_primary_10_1111_bcp_12789 crossref_primary_10_1080_15563650_2019_1675886 crossref_primary_10_3109_15563650_2015_1121545 crossref_primary_10_1016_j_ymgme_2025_109176 crossref_primary_10_1111_bcp_12819 crossref_primary_10_1136_emermed_2024_214533 crossref_primary_10_1016_j_jemermed_2015_12_004 crossref_primary_10_1016_j_neo_2021_02_001 crossref_primary_10_2147_JIR_S306849 crossref_primary_10_1136_emermed_2018_207515_2 crossref_primary_10_3109_15563650_2016_1159309 crossref_primary_10_1080_15563650_2019_1579914 crossref_primary_10_1007_s12072_017_9793_2 crossref_primary_10_1016_j_cld_2016_08_012 crossref_primary_10_3109_15563650_2014_906213 crossref_primary_10_1016_j_lfs_2024_122732 crossref_primary_10_5599_jese_2841 crossref_primary_10_1111_bcp_13063 crossref_primary_10_1097_01_JAA_0000554235_40113_c5 crossref_primary_10_1002_sim_6508 crossref_primary_10_1016_j_intimp_2017_06_027 crossref_primary_10_3389_fphar_2022_876868 crossref_primary_10_1007_s00103_019_03024_7 crossref_primary_10_1007_s11684_017_0550_7 crossref_primary_10_1371_journal_pone_0122781 crossref_primary_10_1016_S0140_6736_14_60680_2 crossref_primary_10_1016_j_jsps_2015_04_004 crossref_primary_10_1111_1742_6723_12610 crossref_primary_10_1186_s12920_020_0705_2 crossref_primary_10_1016_j_cgh_2015_06_020 crossref_primary_10_1586_17512433_2016_1154786 crossref_primary_10_1186_s13613_020_00762_9 crossref_primary_10_1111_bcp_14024 crossref_primary_10_3389_fphar_2024_1384834 crossref_primary_10_1016_j_jece_2023_110193 crossref_primary_10_1016_j_jhep_2025_05_008 crossref_primary_10_1111_bcp_12362 crossref_primary_10_1111_bcp_15199 crossref_primary_10_1007_s00580_025_03682_x crossref_primary_10_1093_ajhp_zxaa178 crossref_primary_10_1080_17512433_2021_1946392 crossref_primary_10_1016_j_ccc_2021_03_005 crossref_primary_10_1186_s40064_016_3240_z crossref_primary_10_1111_bcp_13214 crossref_primary_10_1007_s13181_024_01010_3 crossref_primary_10_1080_15563650_2022_2152350 crossref_primary_10_1111_cts_13009 crossref_primary_10_1016_j_cld_2018_01_007 crossref_primary_10_3109_15563650_2015_1024953 crossref_primary_10_1007_s00228_017_2380_6 crossref_primary_10_1016_j_jelechem_2024_118689 crossref_primary_10_1080_17425255_2023_2259787 crossref_primary_10_1177_0960327119833740 crossref_primary_10_1016_S1872_2067_15_61101_9 crossref_primary_10_1016_j_ejso_2019_10_033 crossref_primary_10_1016_j_redox_2025_103774 crossref_primary_10_1111_bcp_14495 crossref_primary_10_1136_bcr_2016_218667 crossref_primary_10_1016_j_snb_2020_129128 crossref_primary_10_3109_15563650_2016_1165952 crossref_primary_10_1016_S2468_1253_17_30266_2 crossref_primary_10_1016_j_mpmed_2015_12_014 crossref_primary_10_1002_adhm_202300571 crossref_primary_10_1016_j_mpmed_2019_12_017 crossref_primary_10_1136_bmj_l6791 crossref_primary_10_1097_FAD_0000000000000015 crossref_primary_10_1016_j_jhep_2025_07_032 crossref_primary_10_1016_j_redox_2018_04_019 crossref_primary_10_1093_toxsci_kfae031 crossref_primary_10_3389_fimmu_2023_1308477 crossref_primary_10_1136_emermed_2024_214054 crossref_primary_10_1177_0960327114531993 crossref_primary_10_1111_bcp_13279 crossref_primary_10_1007_s00063_017_0282_0 crossref_primary_10_1080_00498254_2022_2128934 crossref_primary_10_1080_14740338_2021_1955854 crossref_primary_10_1136_emermed_2021_212180 crossref_primary_10_1016_j_ajem_2020_07_052 crossref_primary_10_1002_cpt_2541 crossref_primary_10_1111_1751_7915_70083 crossref_primary_10_12968_hmed_2016_77_10_575 crossref_primary_10_1111_bcp_15201 crossref_primary_10_3109_15563650_2015_1115057 crossref_primary_10_1080_15563650_2018_1517881 crossref_primary_10_3109_15563650_2015_1115055 crossref_primary_10_1002_ciuz_201500720 crossref_primary_10_1080_15563650_2023_2293452 crossref_primary_10_1016_j_mpmed_2024_03_013 crossref_primary_10_1016_j_tox_2024_153900 crossref_primary_10_1016_S0140_6736_14_60679_6 crossref_primary_10_1136_bcr_2020_234702 crossref_primary_10_1080_15563650_2017_1317349 crossref_primary_10_1080_10520295_2025_2486453 crossref_primary_10_1016_j_taap_2022_116251 crossref_primary_10_1111_bcp_12604 crossref_primary_10_1111_1742_6723_12373 crossref_primary_10_1097_MD_0000000000034872 crossref_primary_10_1007_s10049_014_1871_6 crossref_primary_10_3109_15563650_2015_1066507 crossref_primary_10_1007_s40278_013_7684_4 |
| Cites_doi | 10.1081/CLT-100102406 10.1097/WOX.0b013e318211496c 10.1002/hep.26294 10.1080/15563650802665587 10.1002/14651858.CD004125.pub2 10.1136/bmj.d2218 10.3109/15563650.2012.746424 10.1016/S0140-6736(77)90612-2 10.3109/15563650.2012.659252 10.1056/NEJM198812153192401 10.1097/00007691-200012000-00015 10.1345/aph.1K685 10.3109/15563650.2013.799677 10.1136/bmj.2.6198.1097 10.1093/qjmed/hct062 10.1016/j.annemergmed.2004.08.040 10.1056/NEJMct0708278 10.1046/j.0306-5251.2001.01490.x 10.1080/15563650802245497 10.1007/BF00558131 10.1016/j.aaen.2003.07.001 10.1002/hep.24538 |
| ContentType | Journal Article |
| Copyright | 2014 Bateman et al. Open Access article distributed under the terms of CC BY Bateman et al. Open Access article distributed under the terms of CC BY 2015 INIST-CNRS Copyright © 2014 Bateman et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Feb 22, 2014 2014. Bateman et al. Open Access article distributed under the terms of CC BY. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2014 Bateman et al. Open Access article distributed under the terms of CC BY – notice: Bateman et al. Open Access article distributed under the terms of CC BY – notice: 2015 INIST-CNRS – notice: Copyright © 2014 Bateman et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Feb 22, 2014 – notice: 2014. Bateman et al. Open Access article distributed under the terms of CC BY. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 6I. AAFTH AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 |
| DOI | 10.1016/S0140-6736(13)62062-0 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) One Sustainability ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central British Nursing Index (BNI) (1985 to Present) ProQuest Health & Medical Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database ProQuest Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest One Psychology MEDLINE ProQuest One Psychology British Nursing Index |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 704 |
| ExternalDocumentID | 3225131051 24290406 28175154 10_1016_S0140_6736_13_62062_0 S0140673613620620 1_s2_0_S0140673613620620 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom--UK United States--US England Scotland |
| GeographicLocations_xml | – name: United Kingdom--UK – name: United States--US – name: England – name: Scotland |
| GrantInformation | Chief Scientist Office of the Scottish Government. |
| GrantInformation_xml | – fundername: Chief Scientist Office grantid: SCD/05 – fundername: Chief Scientist Office grantid: CZB/4/722 |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHHHB AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UQL UV1 WOW X7M XAX XDU YYM Z5R ZMT ~HD .GJ 04C 3EH 3O- 3V. 41~ 88A 8WZ A6W AACTN AAEJM AAKAS AAQXK AAYOK ABDBF ABTAH ABWVN ACRPL ACRZS ACUHS ADMUD ADNMO ADZCM AFCTW AFFNX AFKWA AHQJS AJJEV AJOXV AKVCP ALIPV AMFUW ARTTT ASPBG AVWKF AZFZN D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H M0L M41 MVM OVD PKN Q~Q RIG SDF SV3 TEORI TH9 UHU WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 6I. AAFTH 9DU AAYXX ADXHL AFFHD AGQPQ AIGII CITATION IQODW AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO |
| ID | FETCH-LOGICAL-c640t-5b19f5df074af4eacdb17af97911a5150cfcdae1bf2814ef11fa4d2425845d1b3 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 177 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000331653300030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Sun Sep 28 00:29:07 EDT 2025 Thu Oct 02 11:03:27 EDT 2025 Tue Oct 07 07:38:42 EDT 2025 Sun Nov 02 23:40:36 EST 2025 Mon Jul 21 05:52:59 EDT 2025 Wed Apr 02 07:26:30 EDT 2025 Tue Nov 18 22:51:05 EST 2025 Sat Nov 29 05:12:01 EST 2025 Sat Jan 11 15:49:18 EST 2025 Sun Feb 23 10:18:51 EST 2025 Tue Oct 14 19:31:00 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9918 |
| Keywords | Thiol Intravenous administration Toxicity Antimigrainous agent Acetylcysteine Antioxidant Randomized controlled trial Medicine Mucolytic Paracetamol Reduction Analgesic Treatment Antipyretic Secondary effect Clinical trial Poisoning |
| Language | English |
| License | http://creativecommons.org/licenses/by/3.0 CC BY 4.0 Copyright © 2014 Bateman et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c640t-5b19f5df074af4eacdb17af97911a5150cfcdae1bf2814ef11fa4d2425845d1b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 content type line 23 ObjectType-Undefined-3 ObjectType-Evidence Based Healthcare-3 ObjectType-Feature-1 |
| OpenAccessLink | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673613620620 |
| PMID | 24290406 |
| PQID | 1500807495 |
| PQPubID | 40246 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1523400402 proquest_miscellaneous_1501837553 proquest_journals_3151040809 proquest_journals_1500807495 pubmed_primary_24290406 pascalfrancis_primary_28175154 crossref_citationtrail_10_1016_S0140_6736_13_62062_0 crossref_primary_10_1016_S0140_6736_13_62062_0 elsevier_sciencedirect_doi_10_1016_S0140_6736_13_62062_0 elsevier_clinicalkeyesjournals_1_s2_0_S0140673613620620 elsevier_clinicalkey_doi_10_1016_S0140_6736_13_62062_0 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-02-22 |
| PublicationDateYYYYMMDD | 2014-02-22 |
| PublicationDate_xml | – month: 02 year: 2014 text: 2014-02-22 day: 22 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2014 |
| Publisher | Elsevier Ltd Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
| References | Pakravan, Waring, Bateman (bib11) 2008; 46 Prescott, Illingworth, Critchley, Stewart, Adam, Proudfoot (bib5) 1979; 2 Simons, Ardusso, Bilò (bib21) 2011; 4 Rumack, Bateman (bib9) 2012; 50 Thanacoody, Gray, Dear (bib19) 2013; 14 Heard (bib2) 2008; 359 (bib16) 2009 Fathalla, Hill, Hodson, Salih, Thomas (bib15) 2008; 46 Wright, Anderson, Lesko, Woolf, Linakis, Lewander (bib27) 1999; 37 (bib20) 2012 Antoine, Dear, Starkey Lewis (bib23) 2013; 58 Schmidt (bib30) 2013; 51 (bib8) April 25, 2013 Ferner, Langford, Anton, Hutchings, Bateman, Routledge (bib13) 2001; 52 Bronstein, Spyker, Cantilena, Rumack, Dart (bib4) 2012; 50 Sandilands, Bateman (bib12) 2009; 47 Waring, Pettie, Dow, Bateman (bib29) 2006; 44 (bib3) Nov 1, 2012 Brok, Buckley, Gluud (bib26) 2006; 2 Al-Hourani, Mansi, Pettie, Dow, Bateman, Dear (bib25) 2013; 106 Ferner, Dear, Bateman (bib1) 2011; 342 Starkey Lewis, Dear, Platt (bib24) 2011; 54 Kerr, Dawson, Whyte (bib17) 2005; 45 Prescott, Ballantyne, Park, Adriaenssens, Proudfoot (bib6) 1977; 310 Prescott, Donovan, Jarvie, Proudfoot (bib18) 1989; 37 Whyte, Buckley, Reith, Goodhew, Seldon, Dawson (bib22) 2000; 22 Hayes, Klein-Schwartz, Doyon (bib14) 2008; 42 Smilkstein, Knapp, Kulig, Rumack (bib7) 1988; 319 Lynch, Robertson (bib10) 2004; 12 Carlisle, Stevenson (bib28) 2006; 3 Rumack (10.1016/S0140-6736(13)62062-0_bib9) 2012; 50 Thanacoody (10.1016/S0140-6736(13)62062-0_bib19) 2013; 14 Fathalla (10.1016/S0140-6736(13)62062-0_bib15) 2008; 46 Sandilands (10.1016/S0140-6736(13)62062-0_bib12) 2009; 47 Ferner (10.1016/S0140-6736(13)62062-0_bib13) 2001; 52 Simons (10.1016/S0140-6736(13)62062-0_bib21) 2011; 4 Lynch (10.1016/S0140-6736(13)62062-0_bib10) 2004; 12 Ferner (10.1016/S0140-6736(13)62062-0_bib1) 2011; 342 (10.1016/S0140-6736(13)62062-0_bib16) 2009 Prescott (10.1016/S0140-6736(13)62062-0_bib18) 1989; 37 Smilkstein (10.1016/S0140-6736(13)62062-0_bib7) 1988; 319 Pakravan (10.1016/S0140-6736(13)62062-0_bib11) 2008; 46 Al-Hourani (10.1016/S0140-6736(13)62062-0_bib25) 2013; 106 Antoine (10.1016/S0140-6736(13)62062-0_bib23) 2013; 58 Brok (10.1016/S0140-6736(13)62062-0_bib26) 2006; 2 Whyte (10.1016/S0140-6736(13)62062-0_bib22) 2000; 22 Heard (10.1016/S0140-6736(13)62062-0_bib2) 2008; 359 (10.1016/S0140-6736(13)62062-0_bib20) 2012 Waring (10.1016/S0140-6736(13)62062-0_bib29) 2006; 44 Kerr (10.1016/S0140-6736(13)62062-0_bib17) 2005; 45 Prescott (10.1016/S0140-6736(13)62062-0_bib6) 1977; 310 Schmidt (10.1016/S0140-6736(13)62062-0_bib30) 2013; 51 Bronstein (10.1016/S0140-6736(13)62062-0_bib4) 2012; 50 Prescott (10.1016/S0140-6736(13)62062-0_bib5) 1979; 2 Wright (10.1016/S0140-6736(13)62062-0_bib27) 1999; 37 Hayes (10.1016/S0140-6736(13)62062-0_bib14) 2008; 42 Carlisle (10.1016/S0140-6736(13)62062-0_bib28) 2006; 3 Starkey Lewis (10.1016/S0140-6736(13)62062-0_bib24) 2011; 54 24759248 - Lancet. 2014 Apr 19;383(9926):1383. doi: 10.1016/S0140-6736(14)60680-2. 24759246 - Lancet. 2014 Apr 19;383(9926):1382. doi: 10.1016/S0140-6736(14)60679-6. 24290402 - Lancet. 2014 Feb 22;383(9918):672-4. doi: 10.1016/S0140-6736(13)62303-X. 27203656 - Lancet. 2016 May 7;387(10031):1908. doi: 10.1016/S0140-6736(16)30423-8. |
| References_xml | – volume: 14 start-page: 20 year: 2013 ident: bib19 article-title: Scottish and Newcastle Antiemetic Pre-treatment for paracetamol poisoning study (SNAP) publication-title: BMC Clin Pharmacol – volume: 47 start-page: 81 year: 2009 end-page: 88 ident: bib12 article-title: Adverse reactions associated with acetylcysteine publication-title: Clin Toxicol – volume: 106 start-page: 541 year: 2013 end-page: 546 ident: bib25 article-title: The predictive value of hospital admission serum alanine transaminase activity in patients treated for paracetamol overdose publication-title: QJM – volume: 310 start-page: 432 year: 1977 end-page: 434 ident: bib6 article-title: Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine publication-title: Lancet – volume: 51 start-page: 467 year: 2013 end-page: 472 ident: bib30 article-title: Identification of patients at risk of anaphylactoid reactions to N-acetylcysteine in the treatment of paracetamol overdose publication-title: Clin Toxicol – year: 2009 ident: bib16 publication-title: British National Formulary – volume: 46 start-page: 697 year: 2008 end-page: 702 ident: bib11 article-title: Risk factors and mechanisms of anaphylactoid reactions to acetylcysteine in acetaminophen overdose publication-title: Clin Toxicol – volume: 37 start-page: 501 year: 1989 end-page: 506 ident: bib18 article-title: The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage publication-title: Eur J Clin Pharmacol – volume: 359 start-page: 285 year: 2008 end-page: 292 ident: bib2 article-title: Acetylcysteine for acetaminophen poisoning publication-title: N Engl J Med – volume: 342 start-page: d2218 year: 2011 ident: bib1 article-title: Management of paracetamol poisoning publication-title: BMJ – year: 2012 ident: bib20 publication-title: British National Formulary – volume: 42 start-page: 766 year: 2008 end-page: 770 ident: bib14 article-title: Frequency of medication errors with 21-hour acetylcysteine for acetaminophen overdose publication-title: Ann Pharmacother – volume: 58 start-page: 777 year: 2013 end-page: 787 ident: bib23 article-title: Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital publication-title: Hepatology – volume: 37 start-page: 35 year: 1999 end-page: 42 ident: bib27 article-title: Effect of metoclopramide dose on preventing emesis after oral administration of N-acetylcysteine for acetaminophen overdose publication-title: J Toxicol Clin Toxicol – volume: 45 start-page: 402 year: 2005 end-page: 408 ident: bib17 article-title: The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N-acetylcysteine publication-title: Ann Emerg Med – volume: 44 start-page: 441 year: 2006 end-page: 442 ident: bib29 article-title: Paracetamol appears to protect against N-acetylcysteine-induced anaphylactoid reactions publication-title: Clin Toxicol – volume: 319 start-page: 1557 year: 1988 end-page: 1562 ident: bib7 article-title: Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose: analysis of the national multicenter study (1976 to 1985) publication-title: N Engl J Med – volume: 3 year: 2006 ident: bib28 article-title: Drugs for preventing postoperative nausea and vomiting publication-title: Cochrane Database Syst Rev – year: April 25, 2013 ident: bib8 article-title: Benefit risk profile of acetylcysteine in the management of paracetamol overdose – volume: 50 start-page: 911 year: 2012 end-page: 1164 ident: bib4 article-title: 2011 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th annual report publication-title: Clin Toxicol – volume: 54 start-page: 1767 year: 2011 end-page: 1776 ident: bib24 article-title: Circulating microRNAs as potential markers of human drug-induced liver injury publication-title: Hepatology – volume: 50 start-page: 91 year: 2012 end-page: 98 ident: bib9 article-title: Acetaminophen and acetylcysteine dose and duration: past, present and future publication-title: Clin Toxicol – volume: 4 start-page: 13 year: 2011 end-page: 36 ident: bib21 article-title: World Allergy Organization guidelines for the assessment and management of anaphylaxis publication-title: World Allergy Organ J – volume: 22 start-page: 742 year: 2000 end-page: 748 ident: bib22 article-title: Acetaminophen causes an increased international normalized ratio by reducing functional factor VII publication-title: Ther Drug Monit – year: Nov 1, 2012 ident: bib3 article-title: Hospital episode statistics, admitted patient care—England 2011–12: primary diagnosis, 4 characters table [.xls] – volume: 2 start-page: 1097 year: 1979 end-page: 1100 ident: bib5 article-title: Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning publication-title: BMJ – volume: 46 start-page: 401 year: 2008 end-page: 402 ident: bib15 article-title: Inaccuracies in acetylcysteine dose calculation or infusion rates in patients with and without anaphylactoid reactions publication-title: Clin Toxicol – volume: 2 year: 2006 ident: bib26 article-title: Interventions for paracetamol (acetaminophen) overdose publication-title: Cochrane Database Syst Rev – volume: 52 start-page: 573 year: 2001 end-page: 577 ident: bib13 article-title: Random and systematic medication errors in routine clinical practice: a multicentre study of infusions using acetylcysteine as an example publication-title: Br J Clin Pharmacol – volume: 12 start-page: 10 year: 2004 end-page: 15 ident: bib10 article-title: Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study publication-title: Accid Emerg Nurs – volume: 37 start-page: 35 year: 1999 ident: 10.1016/S0140-6736(13)62062-0_bib27 article-title: Effect of metoclopramide dose on preventing emesis after oral administration of N-acetylcysteine for acetaminophen overdose publication-title: J Toxicol Clin Toxicol doi: 10.1081/CLT-100102406 – volume: 4 start-page: 13 year: 2011 ident: 10.1016/S0140-6736(13)62062-0_bib21 article-title: World Allergy Organization guidelines for the assessment and management of anaphylaxis publication-title: World Allergy Organ J doi: 10.1097/WOX.0b013e318211496c – volume: 58 start-page: 777 year: 2013 ident: 10.1016/S0140-6736(13)62062-0_bib23 article-title: Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital publication-title: Hepatology doi: 10.1002/hep.26294 – volume: 47 start-page: 81 year: 2009 ident: 10.1016/S0140-6736(13)62062-0_bib12 article-title: Adverse reactions associated with acetylcysteine publication-title: Clin Toxicol doi: 10.1080/15563650802665587 – volume: 3 year: 2006 ident: 10.1016/S0140-6736(13)62062-0_bib28 article-title: Drugs for preventing postoperative nausea and vomiting publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD004125.pub2 – volume: 342 start-page: d2218 year: 2011 ident: 10.1016/S0140-6736(13)62062-0_bib1 article-title: Management of paracetamol poisoning publication-title: BMJ doi: 10.1136/bmj.d2218 – volume: 50 start-page: 911 year: 2012 ident: 10.1016/S0140-6736(13)62062-0_bib4 article-title: 2011 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th annual report publication-title: Clin Toxicol doi: 10.3109/15563650.2012.746424 – volume: 310 start-page: 432 year: 1977 ident: 10.1016/S0140-6736(13)62062-0_bib6 article-title: Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine publication-title: Lancet doi: 10.1016/S0140-6736(77)90612-2 – volume: 50 start-page: 91 year: 2012 ident: 10.1016/S0140-6736(13)62062-0_bib9 article-title: Acetaminophen and acetylcysteine dose and duration: past, present and future publication-title: Clin Toxicol doi: 10.3109/15563650.2012.659252 – volume: 14 start-page: 20 year: 2013 ident: 10.1016/S0140-6736(13)62062-0_bib19 article-title: Scottish and Newcastle Antiemetic Pre-treatment for paracetamol poisoning study (SNAP) publication-title: BMC Clin Pharmacol – year: 2009 ident: 10.1016/S0140-6736(13)62062-0_bib16 – year: 2012 ident: 10.1016/S0140-6736(13)62062-0_bib20 – volume: 319 start-page: 1557 year: 1988 ident: 10.1016/S0140-6736(13)62062-0_bib7 article-title: Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose: analysis of the national multicenter study (1976 to 1985) publication-title: N Engl J Med doi: 10.1056/NEJM198812153192401 – volume: 22 start-page: 742 year: 2000 ident: 10.1016/S0140-6736(13)62062-0_bib22 article-title: Acetaminophen causes an increased international normalized ratio by reducing functional factor VII publication-title: Ther Drug Monit doi: 10.1097/00007691-200012000-00015 – volume: 46 start-page: 401 year: 2008 ident: 10.1016/S0140-6736(13)62062-0_bib15 article-title: Inaccuracies in acetylcysteine dose calculation or infusion rates in patients with and without anaphylactoid reactions publication-title: Clin Toxicol – volume: 42 start-page: 766 year: 2008 ident: 10.1016/S0140-6736(13)62062-0_bib14 article-title: Frequency of medication errors with 21-hour acetylcysteine for acetaminophen overdose publication-title: Ann Pharmacother doi: 10.1345/aph.1K685 – volume: 44 start-page: 441 year: 2006 ident: 10.1016/S0140-6736(13)62062-0_bib29 article-title: Paracetamol appears to protect against N-acetylcysteine-induced anaphylactoid reactions publication-title: Clin Toxicol – volume: 51 start-page: 467 year: 2013 ident: 10.1016/S0140-6736(13)62062-0_bib30 article-title: Identification of patients at risk of anaphylactoid reactions to N-acetylcysteine in the treatment of paracetamol overdose publication-title: Clin Toxicol doi: 10.3109/15563650.2013.799677 – volume: 2 year: 2006 ident: 10.1016/S0140-6736(13)62062-0_bib26 article-title: Interventions for paracetamol (acetaminophen) overdose publication-title: Cochrane Database Syst Rev – volume: 2 start-page: 1097 year: 1979 ident: 10.1016/S0140-6736(13)62062-0_bib5 article-title: Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning publication-title: BMJ doi: 10.1136/bmj.2.6198.1097 – volume: 106 start-page: 541 year: 2013 ident: 10.1016/S0140-6736(13)62062-0_bib25 article-title: The predictive value of hospital admission serum alanine transaminase activity in patients treated for paracetamol overdose publication-title: QJM doi: 10.1093/qjmed/hct062 – volume: 45 start-page: 402 year: 2005 ident: 10.1016/S0140-6736(13)62062-0_bib17 article-title: The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N-acetylcysteine publication-title: Ann Emerg Med doi: 10.1016/j.annemergmed.2004.08.040 – volume: 359 start-page: 285 year: 2008 ident: 10.1016/S0140-6736(13)62062-0_bib2 article-title: Acetylcysteine for acetaminophen poisoning publication-title: N Engl J Med doi: 10.1056/NEJMct0708278 – volume: 52 start-page: 573 year: 2001 ident: 10.1016/S0140-6736(13)62062-0_bib13 article-title: Random and systematic medication errors in routine clinical practice: a multicentre study of infusions using acetylcysteine as an example publication-title: Br J Clin Pharmacol doi: 10.1046/j.0306-5251.2001.01490.x – volume: 46 start-page: 697 year: 2008 ident: 10.1016/S0140-6736(13)62062-0_bib11 article-title: Risk factors and mechanisms of anaphylactoid reactions to acetylcysteine in acetaminophen overdose publication-title: Clin Toxicol doi: 10.1080/15563650802245497 – volume: 37 start-page: 501 year: 1989 ident: 10.1016/S0140-6736(13)62062-0_bib18 article-title: The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage publication-title: Eur J Clin Pharmacol doi: 10.1007/BF00558131 – volume: 12 start-page: 10 year: 2004 ident: 10.1016/S0140-6736(13)62062-0_bib10 article-title: Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study publication-title: Accid Emerg Nurs doi: 10.1016/j.aaen.2003.07.001 – volume: 54 start-page: 1767 year: 2011 ident: 10.1016/S0140-6736(13)62062-0_bib24 article-title: Circulating microRNAs as potential markers of human drug-induced liver injury publication-title: Hepatology doi: 10.1002/hep.24538 – reference: 24759246 - Lancet. 2014 Apr 19;383(9926):1382. doi: 10.1016/S0140-6736(14)60679-6. – reference: 27203656 - Lancet. 2016 May 7;387(10031):1908. doi: 10.1016/S0140-6736(16)30423-8. – reference: 24290402 - Lancet. 2014 Feb 22;383(9918):672-4. doi: 10.1016/S0140-6736(13)62303-X. – reference: 24759248 - Lancet. 2014 Apr 19;383(9926):1383. doi: 10.1016/S0140-6736(14)60680-2. |
| SSID | ssj0004605 |
| Score | 2.534223 |
| Snippet | Paracetamol poisoning is common worldwide. It is treated with intravenous acetylcysteine, but the standard regimen is complex and associated with frequent... Summary Background Paracetamol poisoning is common worldwide. It is treated with intravenous acetylcysteine, but the standard regimen is complex and associated... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 697 |
| SubjectTerms | Acetaminophen - antagonists & inhibitors Acetaminophen - poisoning Acetylcysteine Acetylcysteine - administration & dosage Acetylcysteine - adverse effects Adult Aged Alanine Alanine transaminase Alanine Transaminase - metabolism Analgesics Anaphylactoid reactions Antiemetics Antiemetics - administration & dosage Biological and medical sciences Blood pressure Case reports Double-Blind Method Drug Administration Schedule Drug dosages Drug overdose Drug Therapy, Combination Female General aspects Humans Infusions, Intravenous Internal Medicine Intravenous administration Liver Failure, Acute - chemically induced Liver Failure, Acute - prevention & control Male Medical prognosis Medical sciences Middle Aged Nausea - prevention & control Ondansetron - administration & dosage Overdose Paracetamol Patients Placebos Poisoning Poisoning - drug therapy Poisons Pretreatment Randomization Regulatory approval Risk assessment Side effects Statistical analysis Transaminases Treatment Outcome United Kingdom Vomiting Vomiting - chemically induced Vomiting - prevention & control |
| Title | Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673613620620 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673613620620 https://dx.doi.org/10.1016/S0140-6736(13)62062-0 https://www.ncbi.nlm.nih.gov/pubmed/24290406 https://www.proquest.com/docview/1500807495 https://www.proquest.com/docview/3151040809 https://www.proquest.com/docview/1501837553 https://www.proquest.com/docview/1523400402 |
| Volume | 383 |
| WOSCitedRecordID | wos000331653300030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1474-547X dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1474-547X dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1474-547X dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgQ2gS4vujMCoj8QAPYXbsxAkvCKZNvLRUZaC-RY4_pEml6ZYyiSf-de4cNxVStyHxcmrr_NI4vtz9Yp_vCHnNQUesFiKxtRIJ7mVM4F3FJcZIw52QqZcmFJtQ43Exm5WTOOHWxrDKtU0Mhto2BufID4C4MEzcUmYflmcJVo3C1dVYQuMm2eXou0Gf1fT7tn2RIcR9s4Pn4Gv_4xsu3uYpy9OEXeab7ix1C3fMd6UuLueiwScd3_vf3twndyMbpR879XlAbrjFQ3J7FNfbH5HfU8zsimNHG081Fm9uHY0xIBS3ptBTnB2-CJleqTZu9WtuMDk0wGkfxE6BGVNMMg7t-kczp8sGg5jAa76nmkJ_bQPq5iyNgfNz-BjKiTwm346PTg4_J7FkQ2JyyVZJVvPSZ9ZD17SXYNRtzZX2pQKbqoE6MeON1Y7XPi24dJ5zr6XF155CZpbX4gnZWTQL94xQIFKSK6fyOq-lL8rC5JlJjVTGM-sdGxC5HqzKxHzmWFZjXm0JXOOiCmNcAexdD1t2CT2uA-RrTajWu1XBvlbgcq4Dqm1A10Yr0Va8auG4Do1gLgIUkEWPjESoIzj_8qfDv5S17yPcbwUDIAdkf62R1eZCenXc2iyAFoKxL1g5IK_6ZlAMXFzSCwcahqcA76CyTFx1TCrQZ7B0QJ52D87m-oAYQUv-_Orre0H2gLLKkFQg3Sc7q_Of7iW5ZS5Wp-35MDz-KGcqyAJkcciHZPfT0XgyhW8j1skTlOkoyC9BTlCqyR-Dh2eP |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1ba9RAFB5qFRXEa9XVWkdQ0Ie0mcwkkwgiopaWtotoC_s2TuYChXWzNmulT_4jf6PnTC6LsG196YNvSyZfdjJzLl-ScyHkOQMZsZrzyJaSR5jLGMGziouMEYY5LhIvTGg2IYfDfDQqPi2R310uDIZVdjYxGGpbGXxHvgHEJcbCLUX6dvo9wq5R-HW1a6HRiMWOO_kJj2z1m-0PsL8vkmTz4_77rajtKhCZTMSzKC1Z4VPr4VraC7A7tmRS-0KC2mvw7rHxxmrHSp_kTDjPmNfCIjPPRWpZyeG6l8hlsOMSQ8jkSC7Kwwwh9fOMoY0v_cGXjL_KkjhLovg0X3hjqmvYId-01jid-wYfuHnrf1u92-Rmy7bpu0Y97pAlN7lLru618QT3yK_PWLkWZZNWnmpsTl072sa4UEy9oYf49vs4VLKl2rjZydhg8WuA0z5InwLzp1hEHcb1t2pMpxUGaQEreE01hfW1FaiTs7RNDBjDz9AuZYUcXMjt3yfLk2riHhIKRFEw6WRWZqXweZGbLDWJEdL42HoXD4johEOZtl47tg0ZqwWBeYyrIFMKYOs9bNoULDkPkHWSp7psXPAfClzqeUC5COjq1grWiqkazmvQCGY8QAGZ98iW6DUE7l_-dO0v5ejvEdZbwgaIAVntNEDNJ9KL_8JhDrQXnFkeFwPyrB8GwcCPZ3riQMLwEuD9ZJrys85JOPrEOBmQB42izucHBgNGskdnz-8puba1v7erdreHO4_JdaDnIhRQSFbJ8uzoh3tCrpjj2WF9tBZMDyVfL1pb_wArBry4 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1ba9RAFB5qlSKI98tqrSMo6EPcuSWTCCJiXSy1S9EW-hYnc4HCulmbtdIn_5e_znNyW4Rt60sffFsy-WYnM-fM-SY5F0KecZARZ6SMXKFlhLGMEZxVfGStstxLJYKydbEJPR6nBwfZ7gr53cXCoFtltyfWG7UrLb4jHwJxYZi4JYuHoXWL2N0cvZ19j7CCFH5p7cppNCKy7U9-wvGterO1CWv9XIjRh733H6O2wkBkE8XmUVzwLMQuQL8mKNiDXMG1CZmGLcCApWc2WGc8L4JIufKB82CUQ5aeqtjxQkK_l8hlrWKB7mQ7bG9ZTGbtXr-IHhp-6S--4PJlIlgiInaaXbw2MxWsVmjKbJzOg2t7OLrxP8_kTXK9ZeH0XaM2t8iKn94mazutn8Ed8uszZrRFmaVloAaLVleetr4vFENy6CG-FT-uM9xSY_38ZGIxKTbAae-8T-FEQDG5OrSbb-WEzkp03gK28JoaCnPtSlAz72gbMDCBn3UZlbtk_0Ie_x5ZnZZT_4BQIJCKa6-TIilUSLPUJrEVVmkbmAueDYjqBCW3bR53LCcyyZc47HGZ1_KVA-xVD5s1iUzOAySdFOZdlC7YlRxM7XlAvQzoq3Z3rHKeV3Bfg0YwlzUUkGmPbAlgQ-z-5U83_lKU_hlhvjUsgBqQ9U4b8sVAelVY2iyBDoORS1k2IE_7ZhAM_Khmph4kDLsAq6jjWJ51j5BoK5kYkPuN0i7GB4QQWpKHZ4_vCVkDJc0_bY23H5GrwNpVnVdBrJPV-dEP_5hcscfzw-poo96FKPl60cr6B3B4xYg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reduction+of+adverse+effects+from+intravenous+acetylcysteine+treatment+for+paracetamol+poisoning%3A+a+randomised+controlled+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Bateman%2C+D+Nicholas&rft.au=Dear%2C+James+W&rft.au=Thanacoody%2C+H+K+Ruben&rft.au=Thomas%2C+Simon+H+L&rft.date=2014-02-22&rft.pub=Elsevier+Limited&rft.issn=0140-6736&rft.eissn=1474-547X&rft.volume=383&rft.issue=9918&rft.spage=697&rft_id=info:doi/10.1016%2FS0140-6736%2813%2962062-0&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=3225131051 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673614X6071X%2Fcov150h.gif |